Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Patrick Nachipo, David Hermann, Gerald Quinnan, Melita A. Gordon, Wesley C. Van Voorhis, Pui-Ying Iroh Tam

ABSTRACT

BACKGROUND: Cryptosporidium infection and diarrhea (cryptosporidiosis) is a life-threatening infection in persons with HIV and also in children of 6-18 months of age in the developing world. To date, only nitazoxanide is licensed for treatment of cryptosporidiosis, and only in persons after the first year of life and with healthy immune systems. Clofazimine (CFZ: Lamprene®), an established drug that has been used for leprosy for more than 50 years, recently has been described as effective against Cryptosporidium in vitro and in mouse infections. The efficacy and pharmacokinetics of CFZ in vivo, in HIV-infected patients with cryptosporidial diarrhea are not known. METHODS: CRYPTOFAZ includes a randomized, double-blind, placebo-controlled study of the safety, tolerability and Cryptosporidium inhibitory activity of orally administered CFZ in subjects with HIV infection and chronic diarrhea with Cryptosporidium. An additional open label aspect of the study will compare the pharmacokinetics (PK) of orally administered CFZ in HIV-infected individuals with and without Cryptosporidium-associated diarrhea. The study will recruit a total of 66 subjects. Study participants will be given either CFZ or a placebo for 5 days while in hospital and will be followed up after discharge. Cryptosporidium will be diagnosed by quantitative PCR as the definitive test and by stool ELISA, which will also be used to quantify the shedding of Cryptosporidium in stool. PK will be studied on plasma and stool samples. Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose. DISCUSSION: This study provides an opportunity to explore a possible treatment option for HIV-infected patients with cryptosporidial diarrhea, who, as of now in Malawi and most of sub-Saharan Africa, do not have a definitive treatment apart from supportive care. The strength of this study lies in it being a randomized, double-blind, placebo-controlled trial. If shown to be effective and safe, the findings will also lay a foundation for a future study of the use of CFZ in children 6-18 months of age. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03341767 . Registered on 14 November 2017. More... »

PAGES

456

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13063-018-2846-6

DOI

http://dx.doi.org/10.1186/s13063-018-2846-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106325480

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30139372


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Malawi", 
          "id": "https://www.grid.ac/institutes/grid.10595.38", 
          "name": [
            "University of Malawi College of Medicine, Blantyre, Malawi"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nachipo", 
        "givenName": "Patrick", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bill & Melinda Gates Foundation", 
          "id": "https://www.grid.ac/institutes/grid.418309.7", 
          "name": [
            "Bill and Melinda Gates Foundation, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hermann", 
        "givenName": "David", 
        "id": "sg:person.013354566014.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013354566014.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Emmes Corporation", 
          "id": "https://www.grid.ac/institutes/grid.280434.9", 
          "name": [
            "Emmes Corporation, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinnan", 
        "givenName": "Gerald", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Liverpool", 
          "id": "https://www.grid.ac/institutes/grid.10025.36", 
          "name": [
            "University of Malawi College of Medicine, Blantyre, Malawi", 
            "University of Liverpool, Liverpool, UK", 
            "Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gordon", 
        "givenName": "Melita A.", 
        "id": "sg:person.0654763303.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654763303.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington", 
          "id": "https://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "University of Washington, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Voorhis", 
        "givenName": "Wesley C.", 
        "id": "sg:person.0633073157.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633073157.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Liverpool School of Tropical Medicine", 
          "id": "https://www.grid.ac/institutes/grid.48004.38", 
          "name": [
            "University of Malawi College of Medicine, Blantyre, Malawi", 
            "Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi", 
            "Liverpool School of Tropical Medicine, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iroh Tam", 
        "givenName": "Pui-Ying", 
        "id": "sg:person.0615615045.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615615045.28"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0035-9203(98)90804-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013106404"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(14)70772-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021077182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(14)70772-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021077182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(14)70772-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021077182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(14)70772-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021077182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkr444", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027905186"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pntd.0004729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028944992"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2036.2005.02394.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031393042"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2334-9-195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035125355", 
          "https://doi.org/10.1186/1471-2334-9-195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.36.12.2729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036577719"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkh215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037644693"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00260-15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039090400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m110.200501", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043567876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)11401-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053486184"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083206145", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pntd.0005373", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083533965"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: Cryptosporidium infection and diarrhea (cryptosporidiosis) is a life-threatening infection in persons with HIV and also in children of 6-18\u00a0months of age in the developing world. To date, only nitazoxanide is licensed for treatment of cryptosporidiosis, and only in persons after the first year of life and with healthy immune systems. Clofazimine (CFZ: Lamprene\u00ae), an established drug that has been used for leprosy for more than 50\u00a0years, recently has been described as effective against Cryptosporidium in vitro and in mouse infections. The efficacy and pharmacokinetics of CFZ in vivo, in HIV-infected patients with cryptosporidial diarrhea are not known.\nMETHODS: CRYPTOFAZ includes a randomized, double-blind, placebo-controlled study of the safety, tolerability and Cryptosporidium inhibitory activity of orally administered CFZ in subjects with HIV infection and chronic diarrhea with Cryptosporidium. An additional open label aspect of the study will compare the pharmacokinetics (PK) of orally administered CFZ in HIV-infected individuals with and without Cryptosporidium-associated diarrhea. The study will recruit a total of 66 subjects. Study participants will be given either CFZ or a placebo for 5\u00a0days while in hospital and will be followed up after discharge. Cryptosporidium will be diagnosed by quantitative PCR as the definitive test and by stool ELISA, which will also be used to quantify the shedding of Cryptosporidium in stool. PK will be studied on plasma and stool samples. Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T \u00bd) determined after the last dose.\nDISCUSSION: This study provides an opportunity to explore a possible treatment option for HIV-infected patients with cryptosporidial diarrhea, who, as of now in Malawi and most of sub-Saharan Africa, do not have a definitive treatment apart from supportive care. The strength of this study lies in it being a randomized, double-blind, placebo-controlled trial. If shown to be effective and safe, the findings will also lay a foundation for a future study of the use of CFZ in children 6-18\u00a0months of age.\nTRIAL REGISTRATION: ClinicalTrials.gov, NCT03341767 . Registered on 14 November 2017.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13063-018-2846-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6860279", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial", 
    "pagination": "456", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f831d8f2442fb914992a20d532d417cfb6b37f80ca474771f779bab0607b63bf"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30139372"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101263253"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13063-018-2846-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106325480"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13063-018-2846-6", 
      "https://app.dimensions.ai/details/publication/pub.1106325480"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T22:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000571.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13063-018-2846-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2846-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2846-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2846-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2846-6'


 

This table displays all metadata directly associated to this object as RDF triples.

162 TRIPLES      21 PREDICATES      42 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13063-018-2846-6 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nef4b959a8e8e438a8cab7ce57869f2dc
4 schema:citation sg:pub.10.1186/1471-2334-9-195
5 https://app.dimensions.ai/details/publication/pub.1083206145
6 https://doi.org/10.1016/s0035-9203(98)90804-5
7 https://doi.org/10.1016/s0140-6736(02)11401-2
8 https://doi.org/10.1016/s1473-3099(14)70772-8
9 https://doi.org/10.1074/jbc.m110.200501
10 https://doi.org/10.1093/jac/dkh215
11 https://doi.org/10.1093/jac/dkr444
12 https://doi.org/10.1111/j.1365-2036.2005.02394.x
13 https://doi.org/10.1128/aac.00260-15
14 https://doi.org/10.1128/aac.36.12.2729
15 https://doi.org/10.1371/journal.pntd.0004729
16 https://doi.org/10.1371/journal.pntd.0005373
17 schema:datePublished 2018-12
18 schema:datePublishedReg 2018-12-01
19 schema:description BACKGROUND: Cryptosporidium infection and diarrhea (cryptosporidiosis) is a life-threatening infection in persons with HIV and also in children of 6-18 months of age in the developing world. To date, only nitazoxanide is licensed for treatment of cryptosporidiosis, and only in persons after the first year of life and with healthy immune systems. Clofazimine (CFZ: Lamprene®), an established drug that has been used for leprosy for more than 50 years, recently has been described as effective against Cryptosporidium in vitro and in mouse infections. The efficacy and pharmacokinetics of CFZ in vivo, in HIV-infected patients with cryptosporidial diarrhea are not known. METHODS: CRYPTOFAZ includes a randomized, double-blind, placebo-controlled study of the safety, tolerability and Cryptosporidium inhibitory activity of orally administered CFZ in subjects with HIV infection and chronic diarrhea with Cryptosporidium. An additional open label aspect of the study will compare the pharmacokinetics (PK) of orally administered CFZ in HIV-infected individuals with and without Cryptosporidium-associated diarrhea. The study will recruit a total of 66 subjects. Study participants will be given either CFZ or a placebo for 5 days while in hospital and will be followed up after discharge. Cryptosporidium will be diagnosed by quantitative PCR as the definitive test and by stool ELISA, which will also be used to quantify the shedding of Cryptosporidium in stool. PK will be studied on plasma and stool samples. Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose. DISCUSSION: This study provides an opportunity to explore a possible treatment option for HIV-infected patients with cryptosporidial diarrhea, who, as of now in Malawi and most of sub-Saharan Africa, do not have a definitive treatment apart from supportive care. The strength of this study lies in it being a randomized, double-blind, placebo-controlled trial. If shown to be effective and safe, the findings will also lay a foundation for a future study of the use of CFZ in children 6-18 months of age. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03341767 . Registered on 14 November 2017.
20 schema:genre research_article
21 schema:inLanguage en
22 schema:isAccessibleForFree true
23 schema:isPartOf N8112193f52de4d05a038d9e366ef7906
24 N9c228b440c29400fa399315f3da99948
25 sg:journal.1297400
26 schema:name Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial
27 schema:pagination 456
28 schema:productId N0a1f4ab12f5f4a35ba3c4a97c71625c6
29 N179fb7852b4e481e9717345848c2724d
30 Nbcbc8c812eed448c9f57d523f332a529
31 Nc8bff402ac35416cb0cc65dfef14f38d
32 Ne988466534f341298e74a2d6db1b92ef
33 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106325480
34 https://doi.org/10.1186/s13063-018-2846-6
35 schema:sdDatePublished 2019-04-10T22:42
36 schema:sdLicense https://scigraph.springernature.com/explorer/license/
37 schema:sdPublisher N874cd6d64bc54999a42304b9e8c5b128
38 schema:url https://link.springer.com/10.1186%2Fs13063-018-2846-6
39 sgo:license sg:explorer/license/
40 sgo:sdDataset articles
41 rdf:type schema:ScholarlyArticle
42 N0a1f4ab12f5f4a35ba3c4a97c71625c6 schema:name nlm_unique_id
43 schema:value 101263253
44 rdf:type schema:PropertyValue
45 N1531ad4be7af4e9abb453b26b6855adb schema:affiliation https://www.grid.ac/institutes/grid.280434.9
46 schema:familyName Quinnan
47 schema:givenName Gerald
48 rdf:type schema:Person
49 N179fb7852b4e481e9717345848c2724d schema:name dimensions_id
50 schema:value pub.1106325480
51 rdf:type schema:PropertyValue
52 N36a43a1702304b1abe802b0a397d6f1b schema:affiliation https://www.grid.ac/institutes/grid.10595.38
53 schema:familyName Nachipo
54 schema:givenName Patrick
55 rdf:type schema:Person
56 N8112193f52de4d05a038d9e366ef7906 schema:volumeNumber 19
57 rdf:type schema:PublicationVolume
58 N874cd6d64bc54999a42304b9e8c5b128 schema:name Springer Nature - SN SciGraph project
59 rdf:type schema:Organization
60 N8f3cf536c1084bf493d794d46b68be29 rdf:first sg:person.0633073157.20
61 rdf:rest Na4b18d981d1c4454b100c520f4139ed5
62 N920e7b304252477dbfad4625aeb72920 rdf:first sg:person.0654763303.80
63 rdf:rest N8f3cf536c1084bf493d794d46b68be29
64 N9c228b440c29400fa399315f3da99948 schema:issueNumber 1
65 rdf:type schema:PublicationIssue
66 Na4b18d981d1c4454b100c520f4139ed5 rdf:first sg:person.0615615045.28
67 rdf:rest rdf:nil
68 Nb436c659cbba4f5fadf73608ded88a45 rdf:first sg:person.013354566014.76
69 rdf:rest Ndfb016b4bce142868cf2059f907f7d7a
70 Nbcbc8c812eed448c9f57d523f332a529 schema:name readcube_id
71 schema:value f831d8f2442fb914992a20d532d417cfb6b37f80ca474771f779bab0607b63bf
72 rdf:type schema:PropertyValue
73 Nc8bff402ac35416cb0cc65dfef14f38d schema:name pubmed_id
74 schema:value 30139372
75 rdf:type schema:PropertyValue
76 Ndfb016b4bce142868cf2059f907f7d7a rdf:first N1531ad4be7af4e9abb453b26b6855adb
77 rdf:rest N920e7b304252477dbfad4625aeb72920
78 Ne988466534f341298e74a2d6db1b92ef schema:name doi
79 schema:value 10.1186/s13063-018-2846-6
80 rdf:type schema:PropertyValue
81 Nef4b959a8e8e438a8cab7ce57869f2dc rdf:first N36a43a1702304b1abe802b0a397d6f1b
82 rdf:rest Nb436c659cbba4f5fadf73608ded88a45
83 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
84 schema:name Medical and Health Sciences
85 rdf:type schema:DefinedTerm
86 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
87 schema:name Clinical Sciences
88 rdf:type schema:DefinedTerm
89 sg:grant.6860279 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-018-2846-6
90 rdf:type schema:MonetaryGrant
91 sg:journal.1297400 schema:issn 1468-6708
92 1745-6215
93 schema:name Trials
94 rdf:type schema:Periodical
95 sg:person.013354566014.76 schema:affiliation https://www.grid.ac/institutes/grid.418309.7
96 schema:familyName Hermann
97 schema:givenName David
98 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013354566014.76
99 rdf:type schema:Person
100 sg:person.0615615045.28 schema:affiliation https://www.grid.ac/institutes/grid.48004.38
101 schema:familyName Iroh Tam
102 schema:givenName Pui-Ying
103 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615615045.28
104 rdf:type schema:Person
105 sg:person.0633073157.20 schema:affiliation https://www.grid.ac/institutes/grid.34477.33
106 schema:familyName Van Voorhis
107 schema:givenName Wesley C.
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633073157.20
109 rdf:type schema:Person
110 sg:person.0654763303.80 schema:affiliation https://www.grid.ac/institutes/grid.10025.36
111 schema:familyName Gordon
112 schema:givenName Melita A.
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654763303.80
114 rdf:type schema:Person
115 sg:pub.10.1186/1471-2334-9-195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035125355
116 https://doi.org/10.1186/1471-2334-9-195
117 rdf:type schema:CreativeWork
118 https://app.dimensions.ai/details/publication/pub.1083206145 schema:CreativeWork
119 https://doi.org/10.1016/s0035-9203(98)90804-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013106404
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1016/s0140-6736(02)11401-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053486184
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1016/s1473-3099(14)70772-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021077182
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1074/jbc.m110.200501 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043567876
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1093/jac/dkh215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037644693
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1093/jac/dkr444 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027905186
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1111/j.1365-2036.2005.02394.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1031393042
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1128/aac.00260-15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039090400
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1128/aac.36.12.2729 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036577719
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1371/journal.pntd.0004729 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028944992
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1371/journal.pntd.0005373 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083533965
140 rdf:type schema:CreativeWork
141 https://www.grid.ac/institutes/grid.10025.36 schema:alternateName University of Liverpool
142 schema:name Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi
143 University of Liverpool, Liverpool, UK
144 University of Malawi College of Medicine, Blantyre, Malawi
145 rdf:type schema:Organization
146 https://www.grid.ac/institutes/grid.10595.38 schema:alternateName University of Malawi
147 schema:name University of Malawi College of Medicine, Blantyre, Malawi
148 rdf:type schema:Organization
149 https://www.grid.ac/institutes/grid.280434.9 schema:alternateName Emmes Corporation
150 schema:name Emmes Corporation, Rockville, MD, USA
151 rdf:type schema:Organization
152 https://www.grid.ac/institutes/grid.34477.33 schema:alternateName University of Washington
153 schema:name University of Washington, Seattle, WA, USA
154 rdf:type schema:Organization
155 https://www.grid.ac/institutes/grid.418309.7 schema:alternateName Bill & Melinda Gates Foundation
156 schema:name Bill and Melinda Gates Foundation, Seattle, WA, USA
157 rdf:type schema:Organization
158 https://www.grid.ac/institutes/grid.48004.38 schema:alternateName Liverpool School of Tropical Medicine
159 schema:name Liverpool School of Tropical Medicine, Liverpool, UK
160 Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi
161 University of Malawi College of Medicine, Blantyre, Malawi
162 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...